Loading…
Employees: 384
Size Star Sports Medicine (1609.HK) is a Hong Kong Health Care company (Medical Specialties) with a market value of $367M, the 837th largest of 891 Hong Kong companies the cockpit tracks. Shares closed at HK$52.50 on 6 Nov 2026.
Performance Over six months the shares fell 75.7%, against -9.6% for the median peer and -13.4% for the Hong Kong market (cap-weighted) — lowest of 20 in its peer set.
Growth Revenue grew 23.1% over the last twelve months (peer median +6.9%); the operating margin is 37.2% (peer median 5.7%).
Valuation It trades at 3.7× enterprise value to sales against a peer median of 5.0× (10th cheapest of 20).
Price implies For today's price to make sense, revenue must grow about -13% a year for seven years (Req g). Recent delivered growth is +37%, so the hurdle is -50 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 50.0 points above its cost of capital (5.6% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | n/a | HK$437M | HK$355M | HK$264M | HK$170M |
| Revenue growth | — | +23% | +35% | +55% | — |
| Gross profit | n/a | HK$320M | HK$241M | HK$191M | HK$118M |
| EBITDA | n/a | HK$179M | HK$126M | HK$76.6M | HK$48.4M |
| Net income | n/a | HK$149M | HK$103M | HK$63.1M | HK$46.9M |
| Free cash flow | n/a | HK$135M | HK$73.0M | HK$64.8M | HK$56.8M |
| Capital expenditure | n/a | HK$37.1M | HK$29.4M | HK$23.5M | HK$9.90M |
| Total debt | n/a | HK$36.3M | HK$24.0M | HK$9.17M | HK$12.4M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 1609.HK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -31.2% | -3.2% | lowest of 21 |
| 6-month return | -75.7% | -9.6% | lowest of 20 |
| Distance from 52-week high | -82.4% | -40.0% | lowest of 21 |
| Revenue growth (TTM) | +23.1% | +6.9% | 4th highest of 20 |
| Operating margin | 37.2% | 5.7% | highest of 20 |
| EV / Sales | 3.7× | 5.0× | 10th cheapest of 20 |
| Growth the price implies (Req g, 7 yrs) | -13.2% | -7.6% | 4th least demanding of 12 |
| Growth delivered (Del g) | +36.8% | -0.7% | highest of 12 |
| Hurdle (Req g minus delivered) | -50.0 pp | +0.8 pp | least demanding of 12 |
| ROIC minus cost of capital | +50.0 pp | -4.6 pp | highest of 17 |
| EV / EBITDA | 9.1× | 7.9× | 6th cheapest of 11 |
| Net debt / EBITDA | -7.1× | -3.7× | 3rd least indebted of 11 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Star Sports Medicine 1609.HK | Hong Kong | $367M | -76% | +23% | 37% | 3.7× | -13.2% | +36.8% |
| IVF HARTMANN VBSN.SW | Switzerland | $364M | -5% | +7% | 14% | 1.1× | -12.7% | -1.3% |
| Mobia Medical MOBI | United States | $373M | n/a | +105% | -145% | 6.4× | n/a | n/a |
| COLTENE CLTN.SW | Switzerland | $361M | +3% | -2% | 8% | 1.4× | 0.1% | -0.7% |
| Jiangsu Apon Medical Technology 300753.SZ | China | $376M | -27% | -15% | -10% | 8.0× | 22.4% | -5.1% |
| InBody 041830.KS | South Korea | $378M | +43% | +21% | 19% | 1.4× | -7.6% | +16.9% |
| Chongqing Xishan Science and Technology 688576.SS | China | $356M | -26% | -23% | -29% | 6.5× | n/a | n/a |
| Yantai Zhenghai Bio-Tech 300653.SZ | China | $380M | -23% | -8% | 17% | 6.0× | 20.0% | +4.4% |
| Shenzhen Bioeasy Biotechnology 300942.SZ | China | $352M | -27% | +12% | -2% | 8.1× | n/a | n/a |
| Embecta EMBC | United States | $351M | +70% | -8% | 26% | 1.6× | -19.9% | -0.1% |
| Nanjing Medlander Medical Technology 688273.SS | China | $385M | -44% | -12% | 8% | 5.0× | 39.0% | +5.2% |
| Clarity Pharmaceuticals CU6.AX | Australia | $386M | -48% | n/a | n/a | n/a | n/a | n/a |
| ACRO Biomedical 6748.TWO | Taiwan | $347M | +129% | +45% | -178% | 200.7× | n/a | n/a |
| OrbusNeich Medical 6929.HK | Hong Kong | $389M | -3% | +16% | 23% | 1.0× | -18.5% | +15.4% |
| BioNote 377740.KS | South Korea | $343M | -10% | +13% | 16% | 0.8× | -19.8% | -28.5% |
| Chemclin Diagnostics 688468.SS | China | $342M | -23% | -14% | 6% | 6.2× | 31.9% | -4.5% |
| Taidoc Technology 4736.TW | Taiwan | $395M | 0% | -6% | 18% | 1.9× | -8.0% | -6.6% |
| Orchestra BioMed OBIO | United States | $341M | +41% | +986% | -181% | 9.8× | n/a | n/a |
| Stratec SBS.DE | Germany | $341M | +41% | -3% | 3% | 1.6× | n/a | n/a |
| Peijia Medical 9996.HK | Hong Kong | $340M | -34% | +21% | -13% | 2.9× | n/a | n/a |
| CapsoVision CV | United States | $336M | -11% | +15% | -217% | 23.6× | n/a | n/a |